<DOC>
	<DOCNO>NCT02742103</DOCNO>
	<brief_summary>This study phase 2 , multicenter , double-blind , randomize , placebo control , parallel-group study investigate renal safety tolerability multiple dose intravenous ( IV ) administration CSL112 compare placebo subject moderate renal impairment ( RI ) acute myocardial infarction ( AMI ) .</brief_summary>
	<brief_title>A Study CSL112 Adults With Moderate Renal Impairment Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>• Men woman , least 18 year age , evidence moderate renal impairment ( eGFR ≥ 30 &lt; 60 mL/min/1.73 m2 ) myocardial necrosis clinical setting consistent type I ( spontaneous ) acute myocardial infarction ( AMI ) . Symptoms , biomarker elevation electrocardiogram ( ECG ) change index event consistent diagnosis AMI likely due primary myocardial ischemia Ongoing hemodynamic instability Planned coronary artery bypass surgery Evidence hepatobiliary disease History acute kidney injury ( AKI ) previous exposure intravenous contrast agent . History nephrotic range proteinuria . Known history allergy soy bean peanut , immunoglobulin A ( IgA ) deficiency , antibody IgA , hypersensitivity CSL112 component . Other severe comorbid condition , concurrent medication , issue render subject unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>